The Halcyon™ platform is self‐contained, combining a treatment planning (Eclipse) system TPS) with information management and radiation delivery components. The standard TPS beam model is configured and locked down by the vendor. A portal dosimetry‐based system for patient‐specific QA (PSQA) is also included. While ensuring consistency across the user base, this closed model may not be optimal for every department. We set out to commission independent TPS (RayStation 9B, RaySearch Laboratories) and PSQA (PerFraction, Sun Nuclear Corp.) systems for use with the Halcyon linac. The output factors and PDDs for very small fields (0.5 × 0.5 cm²) were collected to augment the standard Varian dataset. The MLC leaf‐end parameters were estimated based on the various static and dynamic tests with simple model fields and honed by minimizing the mean and standard deviation of dose difference between the ion chamber measurements and RayStation Monte Carlo calculations for 15 VMAT and IMRT test plans. Two chamber measurements were taken per plan, in the high (isocenter) and lower dose regions. The ratio of low to high doses ranged from 0.4 to 0.8. All percent dose differences were expressed relative to the local dose. The mean error was 0.0 ± 1.1% (TG119‐style confidence limit ± 2%). Gamma analysis with the helical diode array using the standard 3%Global/2mm criteria resulted in the average passing rate of 99.3 ± 0.5% (confidence limit 98.3%–100%). The average local dose error for all detectors across all plans was 0.2% ± 5.3%. The ion chamber results compared favorably with our recalculation with Eclipse and PerFraction, as well as with several published Eclipse reports. Dose distribution gamma analysis comparisons between RayStation and PerFraction with 2%Local/2mm criteria yielded an average passing rate of 98.5% ± 0.8% (confidence limit 96.9%–100%). It is feasible to use the Halcyon accelerator with independent planning and verification systems without sacrificing dosimetric accuracy.

中文翻译：

---

解锁封闭系统：多供应商环境中环形龙门式直线加速器的剂量学调试

Halcyon™平台是自包含的，将治疗计划（Eclipse）系统TPS与信息管理和辐射传输组件结合在一起。标准TPS光束模型由供应商配置和锁定。还包括一个基于门户剂量法的患者专用QA（PSQA）系统。在确保整个用户群的一致性的同时，这种封闭的模型可能并非对每个部门都是最佳的。我们着手委托与Halcyon直线加速器一起使用的独立TPS（RayStation 9B，RaySearch Laboratories）和PSQA（PerFraction，Sun Nuclear Corp.）系统。极小场（0.5×0.5 cm ²的输出因子和PDD））收集以扩充标准Varian数据集。MLC叶端参数是根据使用简单模型字段进行的各种静态和动态测试估算的，并通过最小化15个VMAT和IMRT测试计划的离子室测量值与RayStation Monte Carlo计算之间的剂量差的平均值和标准偏差来进行细化。每个计划在高剂量（等中心点）和较低剂量区域进行两次腔室测量。低剂量与高剂量之比为0.4至0.8。相对于局部剂量表示所有剂量差异百分比。平均误差为0.0±1.1％（TG119型置信限为±2％）。使用标准3％Global / 2mm标准对螺旋二极管阵列进行的伽马分析得出的平均合格率为99.3±0.5％（置信限98.3％–100％）。在所有计划中，所有探测器的平均局部剂量误差为0.2％±5.3％。离子室的结果与我们使用Eclipse和PerFraction进行的重新计算以及一些已发表的Eclipse报告相比具有优势。使用2％Local / 2mm标准在RayStation和PerFraction之间进行剂量分布伽玛分析比较，得出平均合格率为98.5％±0.8％（置信限96.9％-100％）。将Halcyon加速器用于独立的计划和验证系统是可行的，而不会牺牲剂量精度。使用2％Local / 2mm标准在RayStation和PerFraction之间进行剂量分布伽玛分析比较，得出平均合格率为98.5％±0.8％（置信限96.9％-100％）。将Halcyon加速器用于独立的计划和验证系统是可行的，而不会牺牲剂量精度。使用2％Local / 2mm标准在RayStation和PerFraction之间进行剂量分布伽玛分析比较，得出平均合格率为98.5％±0.8％（置信限96.9％-100％）。将Halcyon加速器用于独立的计划和验证系统是可行的，而不会牺牲剂量精度。